Teva Pharmaceutical Industries Limited (TEVA) – Active Stock Momentum

Ameriprise Financial Inc. owned approximately 0.25% of Teva Pharmaceutical Industries Limited worth $85,853,000 as of its most recent filing with the Securities & Exchange Commission.

TEVA has been the subject of several other reports. The institutional investor held 127,452 shares of the major pharmaceuticals company at the end of 2016Q4, valued at $4.62 million, down from 168,278 at the end of the previous reported quarter. Security National Bank of Sioux City Iowa IA now owns 21,788 shares of the company’s stock valued at $724,000 after purchasing an additional 87 shares during the period. Cetera Investment Advisers bought a new stake in shares of Teva Pharmaceutical Industries Limited in the 2nd quarter valued at $373,000. British Columbia Investment Management Corp increased its position in Teva Pharmaceutical Industries Limited by 8.1% in the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after purchasing an additional 94 shares during the period.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 18.10 on Monday. Oak Associates Ltd. OH now owns 379,924 shares of the company’s stock valued at $12,621,000 after purchasing an additional 2,114 shares during the last quarter. Finally, Paragon Capital Management LLC increased its position in Teva Pharmaceutical Industries Limited by 47.2% in the 1st quarter.

A number of hedge funds and other institutional investors have recently modified their holdings of the business.

“Today’s announcement, coupled with the recent announcement of the sale of Paragard for $1.1 billion, demonstrate Teva’s commitment to delivering on our promise to generate net proceeds of at least $2 billion” from the divestitures, said Yitzhak Peterburg, interim chief executive. Mizuho raised Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $25.00 to $30.00 in a research note on Thursday, June 15th. Reynders Mcveigh Capital Management Llc sold 40,826 shares as Teva Pharmaceutical Industries (TEVA)’s stock declined 15.11%. Maxim Group reissued a “hold” rating and issued a $15.50 price target on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday.

On August 24, 2017 the stock rating was rated “Underperform” in a report from Credit Suisse a cut from the previous “Market Perform” rating.

Institutional investors now hold around $10.77 billion or 60.2% in TEVA stock. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and worldwide copyright & trademark law. The original version of this piece can be viewed at

Teva Pharmaceutical Industries Limited is a pharmaceutical company. Stock’s distance from 52 week High is -65.38% and the distance from 52 week Low is 18.92%. The stock’s market capitalization is $18.39 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). The company earned $6.25 billion during the quarter, compared to the consensus estimate of $6.26 billion. The company’s revenue for the quarter was up 12.9% compared to the same quarter past year. During the same period a year ago, the company earned $1.32 EPS.

Teva Pharmaceutical Industries Limited (TEVA) has an Analysts’ Mean Recommendation of 2.9.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 14th. Wunderlich maintained the shares of CAPL in report on Tuesday, August 11 with “Buy” rating. As per Friday, July 15, the company rating was downgraded by Goldman Sachs. This represents a $0.34 dividend on an annualized basis and a yield of 1.88%. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently -15.36%.

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is involved in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines.

Leave a Reply

Your email address will not be published. Required fields are marked *